Joseph DeVivo - AngioDynamics CEO and President and Director
ANGO Stock | USD 6.03 0.23 3.67% |
CEO
Dr. Joseph M. DeVivo is President Chief Executive Officer Director of the Company. Prior to joining AngioDynamics Mr. DeVivo served as Global President of Smith Nephew Orthopedics. Previously Mr. DeVivo was CEO and President of RITA Medical Systems serving in that capacity at the time AngioDynamics acquired RITA. Prior to RITA Medical Systems Mr. DeVivo served as President Chief Operating Officer and Director of Computer Motion Incorporation . Mr. DeVivo also previously served as Vice President and General Manager of a 350 million division of TYCO Internationals Healthcare Business U.S. SurgicalDavis and Geck Sutures where he was responsible for sales marketing research and development and finance in its vascular business. During his nineyear tenure at U.S. Surgical he held various management positions related to sales and marketing since 2011.
Age | 47 |
Tenure | 13 years |
Address | 14 Plaza Drive, Latham, NY, United States, 12110 |
Phone | 518 795 1400 |
Web | https://www.angiodynamics.com |
AngioDynamics Management Efficiency
The company has return on total asset (ROA) of (0.0481) % which means that it has lost $0.0481 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6242) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to grow to -0.22. In addition to that, Return On Capital Employed is likely to grow to -0.05. At this time, AngioDynamics' Other Assets are very stable compared to the past year. As of the 23rd of April 2024, Other Current Assets is likely to grow to about 4.5 M, while Total Assets are likely to drop about 533.4 M.Similar Executives
Found 4 records | CEO Age | ||
Lennart Flem | National Research Corp | N/A | |
Michael Hays | National Research Corp | 69 | |
Oivind Horpestad | National Research Corp | N/A | |
Jon Kessler | HealthEquity | 56 |
Management Performance
Return On Equity | -0.62 | ||||
Return On Asset | -0.0481 |
AngioDynamics Leadership Team
Elected by the shareholders, the AngioDynamics' board of directors comprises two types of representatives: AngioDynamics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AngioDynamics. The board's role is to monitor AngioDynamics' management team and ensure that shareholders' interests are well served. AngioDynamics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AngioDynamics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ben Davis, Senior Vice President Business Development | ||
Michael Trimarchi, Interim CFO, VP and Global Controller | ||
Jeffrey Gold, Independent Director | ||
Chad Campbell, Senior Vice President and General Manager, Vascular Access | ||
Steven Laporte, Independent Director | ||
David Helsel, Senior Vice President - Global Operations | ||
Jan Reed, Director | ||
Dennis Meteny, Independent Director | ||
Eileen Auen, Director | ||
Wesley Johnson, Independent Director | ||
Mark Stephens, Sr. VP of Admin. | ||
Stephen Trowbridge, Sr. VP, General Counsel and Assistant Secretary | ||
Heather DanielsCariveau, Senior Vice President-Human Resources | ||
Saleem Cheeks, Vice Communications | ||
John Soto, Chief Commercial Officer and Executive VP | ||
Benjamin Davis, Senior Vice President Business Development | ||
Barbara Kucharczyk, Senior Vice President-Global Operations | ||
Robert Simpson, Senior Vice President and General Manager, Peripheral Vascular | ||
Kevin Gould, Independent Director | ||
Michael Greiner, CFO, Executive Vice President | ||
Laura Piccinini, Senior International | ||
Warren Nighan, Senior Vice President-Senior Vice President Quality & Regulatory Affairs | ||
Sriram Venkataraman, Independent Director | ||
Brent Boucher, Senior Vice President and General Manager, Oncology/Surgery | ||
Joseph DeVivo, CEO and President and Director | ||
Scott Centea, Senior Therapies | ||
James Clemmer, President CEO, Director | ||
Caitlin Stefanik, IR Contact Officer | ||
Richard Rosenzweig, Gen VP | ||
Christopher Dailey, IR Contact Officer | ||
Marna BronfenMoore, Senior Resources | ||
Kim Seabury, Senior Vice President Information Technology | ||
Juan Serna, Senior Affairs | ||
Karen Licitra, Independent Director | ||
Gary Barrett, Senior Vice President Quality and Regulatory Affairs | ||
David Burgstahler, Independent Director | ||
Howard Donnelly, Independent Chairman of the Board |
AngioDynamics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AngioDynamics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.62 | ||||
Return On Asset | -0.0481 | ||||
Profit Margin | (0.59) % | ||||
Operating Margin | (0.19) % | ||||
Current Valuation | 176.26 M | ||||
Shares Outstanding | 40.05 M | ||||
Shares Owned By Insiders | 4.99 % | ||||
Shares Owned By Institutions | 91.91 % | ||||
Number Of Shares Shorted | 2.25 M | ||||
Price To Earning | 7.90 X |
Pair Trading with AngioDynamics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.Moving against AngioDynamics Stock
0.66 | FONR | Fonar | PairCorr |
0.65 | NRC | National Research Corp | PairCorr |
0.62 | EVH | Evolent Health Financial Report 1st of May 2024 | PairCorr |
0.57 | VMD | Viemed Healthcare | PairCorr |
0.55 | CVS | CVS Health Corp Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.
The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for AngioDynamics Stock analysis
When running AngioDynamics' price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Revenue Per Share 8.105 | Quarterly Revenue Growth (0.07) | Return On Assets (0.05) | Return On Equity (0.62) |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.